<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/7A0397DD-E0C6-4EA3-8031-B841D2503C4D"><gtr:id>7A0397DD-E0C6-4EA3-8031-B841D2503C4D</gtr:id><gtr:name>Royal Holloway, University of London</gtr:name><gtr:department>Biological Sciences</gtr:department><gtr:address><gtr:line1>Egham Hill</gtr:line1><gtr:line4>Egham</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>TW20 0EX</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7A0397DD-E0C6-4EA3-8031-B841D2503C4D"><gtr:id>7A0397DD-E0C6-4EA3-8031-B841D2503C4D</gtr:id><gtr:name>Royal Holloway, University of London</gtr:name><gtr:address><gtr:line1>Egham Hill</gtr:line1><gtr:line4>Egham</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>TW20 0EX</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name><gtr:address><gtr:line1>BBSRC</gtr:line1><gtr:line2>Polaris House</gtr:line2><gtr:line3>North Star Avenue</gtr:line3><gtr:line4>Swindon</gtr:line4><gtr:postCode>SN2 1UH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/92D0F6C6-2856-4A4B-B0AE-2760AF60FB9D"><gtr:id>92D0F6C6-2856-4A4B-B0AE-2760AF60FB9D</gtr:id><gtr:name>Recipharm Cobra Biologics</gtr:name><gtr:address><gtr:line1>Stephenson Building</gtr:line1><gtr:line2>Science Park</gtr:line2><gtr:line4>Keele</gtr:line4><gtr:postCode>ST5 5SP</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9483A1B3-8C62-47FF-A9BB-F2C852753266"><gtr:id>9483A1B3-8C62-47FF-A9BB-F2C852753266</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Cutting</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=DT%2FF002351%2F1"><gtr:id>A1037CB3-EFBE-4934-8B77-A10AF225A6C6</gtr:id><gtr:title>ORT-VAC: live bacterial vectors for vaccine delivery</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>DT/F002351/1</gtr:grantReference><gtr:abstractText>We aim to revolutionise vaccination by developing an innovative oral vaccine delivery technology. Traditional vaccines require extensive and costly production, purification, formulation and storage, with needles used for administration. We will engineer live enteric ORT-VAC bacteria to carry plasmids expressing antigens. These uniquely enable stable, high-copy number plasmid maintenance without antibiotic resistance or other selectable marker genes, making them particularly suited for delivering DNA vaccines against influenza and HIV, which will also be developed by the consortium. Encapsulation technology will be optimised to enable the bacteria to be stored at ambient temperature, ingested and released into the small intestine, where they will stimulate a protective immune response. ORT-VAC therefore represents a cost-effective platform technology with built-in stability, adjuvanticity and efficacy.</gtr:abstractText><gtr:fund><gtr:end>2011-07-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2008-01-02</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>321553</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We evaluated a novel method for delivering antigens from Mycobacterium tuberculosis (the causative agent of TB) using a bacterium (Salmonella typhi) by the oral route. Salmonella is used as an oral vaccine to typhoid fever where it can be used by the oral route as a pill. We engineered this bacterium to express M. tuberculosis antigens and then demonstrated that when administered by the oral route immune responses to the antigen could be achieved. In principle this offer the potential of using Salmonella as an oral vaccine system for TB.</gtr:description><gtr:exploitationPathways>Further work could be conducted to use the delivery system using new antigens that could be employed for TB vaccination. The oral route of delivery is particularly attractive. The Salmonella system for delivering antigens is currently being exploited by the UK company Prokarium (www.prokarium.com) and our work supports their platform.</gtr:exploitationPathways><gtr:id>1101676B-41CA-4DA5-A6F3-185226603F8C</gtr:id><gtr:outcomeId>5453b6d372aa37.19284460</gtr:outcomeId><gtr:sectors><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>47FD51EF-9C96-420A-B235-C77C443C7241</gtr:id><gtr:title>Oral delivery of a DNA vaccine against tuberculosis using operator-repressor titration in a Salmonella enterica vector.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a94b31de9884a05c64ec5d502ac4427"><gtr:id>8a94b31de9884a05c64ec5d502ac4427</gtr:id><gtr:otherNames>Huang JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>doi_53d00e00ecd8400d</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">DT/F002351/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>99E0B904-CAB5-4511-AFB3-AA6D2B171F97</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Process engineering</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>9C387DA5-CD5F-43E4-AA74-82CBF4DB6617</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Bioprocess Engineering</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>